Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Quarterly Earnings Results, Misses Estimates By $0.61 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61), Briefing.com reports. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the firm earned $9.55 EPS. The company's revenue was down 3.7% compared to the same quarter last year.

Regeneron Pharmaceuticals Trading Up 2.6 %

Regeneron Pharmaceuticals stock traded up $15.61 during mid-day trading on Friday, hitting $605.61. The company's stock had a trading volume of 1,606,415 shares, compared to its average volume of 745,022. The business has a 50 day moving average price of $626.49 and a 200-day moving average price of $709.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals has a 12 month low of $525.99 and a 12 month high of $1,211.20. The stock has a market cap of $66.21 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Regeneron Pharmaceuticals stock. Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 261.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 948 shares of the biopharmaceutical company's stock after purchasing an additional 686 shares during the quarter. Brighton Jones LLC's holdings in Regeneron Pharmaceuticals were worth $675,000 at the end of the most recent quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $892.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.